Pain and inflammation
TNF-α inhibitors
Monoclonal antibodies and fusion proteins that neutralise tumour necrosis factor-α, a key inflammatory cytokine; used in moderate to severe Crohn disease, ulcerative colitis, psoriasis and inflammatory arthritis.
Mécanisme d’action
- TNF-α, made by macrophages and T cells, drives inflammation: it activates endothelium, recruits leucocytes and induces other cytokines.
- Infliximab, adalimumab and others bind TNF-α and stop it reaching its receptors; etanercept is a soluble receptor that traps it.
- Inflammation falls; in Crohn disease, ulcers and fistulae can heal.
- TNF-α is also essential for keeping tuberculosis walled off in granulomas.
Cibles moléculaires
- Tumour necrosis factor-α: Neutralised
Médicaments : TNF-α inhibitors
Monoclonal antibodies
- Infliximab (Chimeric antibody, intravenous.)
- Adalimumab (Human antibody, subcutaneous.)
- Certolizumab and golimumab
Soluble receptor (fusion protein)
- Etanercept (Soluble receptor; not effective in inflammatory bowel disease.)
Indications thérapeutiques
- Moderate to severe Crohn disease, including fistulising disease
- Moderate to severe ulcerative colitis
- Moderate to severe psoriasis and psoriatic arthritis
- Rheumatoid arthritis and ankylosing spondylitis
Maladies traitées
Effets indésirables
- Serious infections, including reactivated tuberculosis and fungal infections
- Infusion and injection-site reactions
- Worsening heart failure
- Demyelinating disease
- Lymphoma (rare)
Contre-indications selon le terrain
- Pulmonary tuberculosis (Contre-indiqué): Without TNF-α, granulomas break down and tuberculosis reactivates, often disseminated. Everyone is screened before starting.
- Active serious infection (Contre-indiqué): Immune defences are weakened.
- Heart failure (Avec précaution): Infliximab worsened moderate to severe heart failure.
- Multiple sclerosis or other demyelinating disease (Avec précaution): They can provoke or worsen demyelination.
Rédigé d’après
- Lippincott Illustrated Reviews: Pharmacology, 7th ed., Ch. 38, Anti-inflammatory, Antipyretic, and Analgesic Agents, Biologic DMARDs: TNF-α inhibitors
- Lippincott Illustrated Reviews: Pharmacology, 7th ed., Ch. 40, Gastrointestinal and Antiemetic Drugs, Drugs used to treat inflammatory bowel disease
- Basic & Clinical Pharmacology (Katzung), 14th ed., Ch. 55, Immunopharmacology, Antibodies against TNF
Ressource pédagogique. Ne constitue pas un avis, un diagnostic ou un traitement médical.